Research programme: GPCR modulators - AstraZeneca/Nxera Pharma
Alternative Names: AZ-3451; AZ-8838; CNS therapeutics - AstraZeneca/Nxera PharmaLatest Information Update: 02 Apr 2024
Price :
$50 *
At a glance
- Originator AstraZeneca; Heptares Therapeutics
- Developer AstraZeneca; Heptares Therapeutics; Nxera Pharma
- Class Analgesics; Anti-inflammatories; Antibodies; Antineoplastics; Small molecules
- Mechanism of Action G protein-coupled receptor antagonists; G protein-coupled receptor modulators; PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Metabolic disorders; Pain
Most Recent Events
- 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
- 28 Jun 2021 No recent reports of development identified for research development in Metabolic-disorders in United Kingdom (Parenteral)
- 28 Jun 2021 No recent reports of development identified for research development in Pain in United Kingdom (Parenteral)